IFNA1 and neoplasm: Based on the described preclinical data, the best next experimental steps should be probably designed within controlled clinical studies that could benefit from the already existing knowledge of previous trials with IFNα in GIST patients, and from the safety and pharmacodynamic information with CIK in various tumor settings.